Vaccination against tumour endothelial marker Robo4 inhibits tumour growth
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 25.06.2026. Verfasst von Fernanda Escobar-Riquelme und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingha…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BBRSC, National Agency for Research and Development, Republic of Türkiye Ministry of National Education.
Abstract (Originalsprache)
Introduction
Targeting tumour antigens is a major challenge in cancer-immunotherapy. We use active vaccination to induce antibodies targeting self-antigen Robo4, which is selectively expressed on tumour vascular endothelium, and supports vascular development. Our previous work showed that a conjugate of Robo4 with a foreign carrier protein induced autoantibodies specific to Robo4, which inhibited angiogenesis and tumour growth.
Methods
To translate the vaccine protocol to exploit a carrier protein used in routine human vaccination schedules, the well-characterized, non-toxic fragment C of tetanus toxin (TTc) was selected as the carrier protein. Recombinant protein Robo4-TTc (R4-TTc) was produced by Robo4 genetically linked to TTc.
Results
Priming with the carrier TTc followed by boost with Robo4-TTc (R4-TTc) efficiently induces strong antibody responses to Robo4 and inhibits tumour growth in LLC1 and 4T1 tumour models. The growth inhibition was correlated with anti-Robo4 IgG1 titres. Furthermore, decreased vessel formation and increased immune cell infiltration in tumours from R4-TTc vaccinated mice in the absence of detectable adverse effects on health.
Conclusion
The data indicate that this vaccination strategy remodels tumour vessels and probably promotes immunogenic pathway activation, therefore repressing tumour growth.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
- Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom.
- Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
- Bioinformatics, the Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
- Department of Cardiovascular Sciences, College of Medicine and Health, The University of Birmingham, Birmingham, United Kingdom.
- Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Science, University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Fernanda Escobar-Riquelme, David Bending, Kai-Michael Toellner, Yang Zhang
Förderung
- BBRSC
- National Agency for Research and Development
- Republic of Türkiye Ministry of National Education
Zitieren
APA
Escobar-Riquelme, F., Kara, M. A., Price, M. J., Hidalgo-Gajardo, A., Carr, H. L., Bending, D., Bicknell, R., Savelyeva, N., Toellner, K. M., & Zhang, Y. (2025). Vaccination against tumour endothelial marker Robo4 inhibits tumour growth. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag005
Vancouver
Escobar-Riquelme F, Kara MA, Price MJ, Hidalgo-Gajardo A, Carr HL, Bending D, et al. Vaccination against tumour endothelial marker Robo4 inhibits tumour growth. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag005
BibTeX
@article{EscobarRiquelme2025,
author = {Escobar-Riquelme, Fernanda and Kara, Muhammet Ali and Price, Michael J and Hidalgo-Gajardo, Angela and Carr, Hayley L and Bending, David and Bicknell, Roy and Savelyeva, Natalia and Toellner, Kai-Michael and Zhang, Yang},
title = {Vaccination against tumour endothelial marker Robo4 inhibits tumour growth},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag005}
}
EUVIMED